Cerus Corporation (CERS) Shares are Up 0.99%

Cerus Corporation (CERS) has been under a strong bear grip, hence the stock is down -7.45% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.45% in the past 1 week. The stock has risen by 0.99% in the past week indicating that the buyers are active at lower levels, but the stock is down -9.32% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 5.3% and the 50-Day Moving Average is 7.62%.The 200 Day SMA reached 1.88% Cerus Corporation is up 7.54% in the last 3-month period. Year-to-Date the stock performance stands at -3.01%.


Cerus Corporation (CERS) : Average target price received by Cerus Corporation (CERS) is $9.7 with an expected standard deviation of $0.45. The most aggressive target on the stock is $10, whereas the most downbeat target is $9. 5 financial analysts are currently covering the stock.

For this week, the average consensus of the company shares are rated as a Strong Buy. Cerus Corporation (NASDAQ:CERS): The stock was completely flat for the day, closing at $6.13 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $6.14, the stock touched an intraday high of $6.29 and a low of $6.06. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $6.13. The total trading volume on Friday was 1,240,084.

Cerus Corporation is a biomedical products company engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Companys INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including HIV, West Nile, SARS, hepatitis B and C; bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company has commercial rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets or platelet system and the INTERCEPT Blood System for plasma or plasma system are being marketed and sold in a number of countries, including the United States, certain countries in Europe, The Commonwealth of Independent States (CIS) and the Middle East. The INTERCEPT Blood System for red blood cells is in development-stage.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.